Ascendis Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush maintained a Buy rating on the stock and has a $220.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yun Zhong’s rating is based on the competitive advantage that Ascendis Pharma’s Yorvipath holds in the treatment of hypoparathyroidism. The feedback from a key opinion leader (KOL) highlighted that Yorvipath maintains a superior clinical profile compared to its competitors, particularly in terms of managing serum calcium levels effectively.
Additionally, the KOL pointed out that the quality-of-life improvements associated with Yorvipath are a significant indicator of its efficacy, which is a critical factor now required by the FDA. The absence of such data from MBX Biosciences’ Phase 2 study further underscores Yorvipath’s competitive edge. These factors collectively contribute to Yun Zhong’s confidence in recommending a Buy rating for Ascendis Pharma’s stock.
Zhong covers the Healthcare sector, focusing on stocks such as MannKind, Ascendis Pharma, and Protagonist Therapeutics. According to TipRanks, Zhong has an average return of -11.6% and a 43.23% success rate on recommended stocks.
In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $230.00 price target.